Caspofungin

Drug Profile

Caspofungin

Alternative Names: Cancidas; Cansidas; Caspofungin acetate; Caspofungin MSD; L 743792; L 743872; MK 0991; MK 991

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antifungals; Echinocandins
  • Mechanism of Action Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aspergillosis; Candidaemia; Candidiasis; Mycoses

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 27 Jan 2014 Phase-II clinical trials in Candidiasis (in infants, in neonates) in USA, Colombia and Turkey (IV)
  • 13 Sep 2013 Merck plans a phase II trial for Candidiasis (in neonates, in infants) in USA (NCT01945281)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top